American Society of Hirudotherapy

Evaluation of gaps in direct oral anticoagulants (DOACs) management in an outpatient underserved clinic: a cross-sectional study.

Research article published in Scientific reports (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsAlghamdi et al. · Scientific reports, 2025

Abstract

DOACs are widely used for stroke prevention in non-valvular atrial fibrillation and treatment of thromboembolism, but gaps in their management can lead to adverse outcomes. In outpatient, underserved clinics, challenges such as inappropriate dosing, lack of monitoring, and improper drug combinations may be more pronounced, necessitating evaluation to optimize patient care and reduce risks. This study assessed the appropriateness of DOAC use and dosing per FDA guidelines, considering renal function, hepatic function, and drug-drug interactions. Secondary objectives focused on evaluating inappropriate aspirin use alongside DOACs. This was a single-center retrospective cohort study. The study was conducted at Texas A&M Health Family Care Clinic (12/24/2022-12/24/2023). Older than 18 years of age and had active prescription of DOAC (apixaban, dabigatran, edoxaban, or rivaroxaban). A total of 125 DOAC patients were included. Inappropriate dosing based on renal function occurred in 16% of cases. DOAC use was unsuitable in two patients with severe hepatic impairment. Major drug interactions resulted in two instances of inappropriate DOAC use. Additionally, about 61% of aspirin usage involved inappropriate combinations with DOACs, as shown in Fig. 1. The study's findings indicate that anticoagulation management in our ambulatory care setting has the potential for further optimization.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdministration, OralAnticoagulantsCross-Sectional StudiesAtrial FibrillationDrug InteractionsDabigatran

Summary

Evaluation of gaps in direct oral anticoagulants (DOACs) management in an outpatient underserved clinic: a cross-sectional study.

Why This Matters for Hirudotherapy

This single-center retrospective cohort of 125 DOAC patients in an underserved outpatient clinic found measurable management gaps: inappropriate renal-function-based dosing in 16% of cases, unsuitable use in severe hepatic impairment, major drug-interaction errors, and inappropriate aspirin-with-DOAC combinations in about 61% of aspirin users. For ASH this documents the real-world fragility of systemic anticoagulant management, the dosing, monitoring, and interaction burdens that local leech-based anticoagulation does not impose, while reinforcing that any anticoagulant strategy demands careful oversight. As a small, single-center retrospective audit it describes practice quality at one site and cannot be generalized; it concerns oral agents only and has no bearing on hirudotherapy efficacy or safety.

Citation

Evaluation of gaps in direct oral anticoagulants (DOACs) management in an outpatient underserved clinic: a cross-sectional study.

Alghamdi et al. · Scientific reports, 2025

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.